The RESTORE-2 trial found high rates of investigator and patient satisfaction with autologous adipose-derived regenerative cell (ADRC)-enriched fat grafting for breast reconstruction after cancer surgery. The procedure also showed improved breast contour and no local cancer recurrences or serious adverse events.
The APOLLO trial demonstrated improvements in cardiac function, blood flow into the heart muscle, and reduced scar formation in patients with acute myocardial infarction. The study found a 52% reduction in left ventricle infarcted area and significant improvement of perfusion defects in ADRC-treated patients.
Researchers from Cytori Therapeutics published a study demonstrating that cell-enriched autologous fat grafts have significantly higher quality and improved blood vessel density compared to traditional grafts. The results show a two-fold increase in long-term retention of cell-enriched grafts.
A head-to-head clinical trial will enroll approximately 400 patients at three world-class sites to compare Telesso's novel guide-wire assisted peripheral IV catheter with the industry standard. The trial aims to reduce safety risks, lessen patient pain and discomfort, and provide cost savings.
The study shows significantly increased disc tissue density and extracellular matrix components at 12 months post treatment, suggesting a potential link between ADRCs and improved disc condition. Viable ADRCs were identified within the discs, indicating a possible novel therapeutic for spinal surgery patients.
In a preclinical safety study, adipose-derived stem cells demonstrated a statistically significant improvement in left ventricular ejection fraction (LVEF) at six-months post-infarction. The treated group showed improved heart function compared to the control group, as measured by both 2D echocardiography and cineangiography.